Repligen/$RGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Ticker

$RGEN
Primary listing

Industry

Life Sciences Tools & Services

Employees

1,778

ISIN

US7599161095

Repligen Metrics

BasicAdvanced
$7.5B
-
-$0.42
1.27
-

What the Analysts think about Repligen

Analyst ratings (Buy, Hold, Sell) for Repligen stock.

Bulls say / Bears say

Repligen's Q1 2025 revenue increased by 10% to $169 million, with adjusted EPS rising 29% to $0.39, surpassing forecasts. (Investing.com)
The company completed the acquisition of Tantti Laboratory Inc., enhancing its offerings in protein and chromatography, and launched AVIPure dsRNA resin for mRNA therapeutics. (StockTitan)
Analysts have set 12-month price targets for Repligen, revealing an average target of $179.88, indicating potential upside from current levels. (Nasdaq)
Repligen's Q4 2024 adjusted EPS decreased to $0.44 from $0.48 in the previous year, and revenue growth was only 1%, indicating potential stagnation. (Investing.com)
The company's stock has seen a -24.53% return over the past year, reflecting investor concerns about its performance. (Investing.com)
Some analysts have downgraded their price targets, with Canaccord Genuity lowering its target from $170 to $150, suggesting reduced confidence in future growth. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Repligen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Repligen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGEN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs